Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited reported a significant increase in its half-year profits, with a net profit after tax of A$15.0 million, marking an 88% rise compared to the previous year. This growth was driven by increased royalty revenue from Acadia, which rose to A$28.3 million. Despite the profit surge, the company did not declare any dividends and completed a share buy-back program worth $39.6 million, reflecting its strategic financial management.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing therapies for neurodevelopmental disorders. The company generates revenue primarily through royalty agreements, notably with Acadia Pharmaceuticals.
Average Trading Volume: 496,304
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.23B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.